|
Earn CME & learn how to integrate mpMRI with ancillary testing to improve csPCa risk assessment and early detection. |
|
CME Program: “Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis”
|
|
Join Stacy Loeb, MD, MSc, PhD (Hon) for a CME presentation on “Incorporating Multiparametric MRI to Guide Prostate Cancer Diagnosis.”
|
|
|
|
In this program, Dr. Loeb discusses the role of mpMRI in clinically significant prostate cancer risk (csPCa) assessment and ways to apply PI-RADS results to clinical decision-making.
|
|
She shares evidence-based strategies for integrating biomarker testing and mpMRI to improve risk stratification and early detection, particularly for high-risk patients.
|
|
Register for this CME program to earn credits while reviewing mpMRI and ancillary tests as tools for your practice.
|
|
|
|
Explore the IsoPSA Test's Clinical Impact
|
|
An extensive portfolio of publications has demonstrated that the IsoPSA Test can improve risk stratification for csPCa1, enhance biopsy decision-making alongside mpMRI2, and predict risk for csPCa over time.3
|
Subscribe to learn more and receive updates when new CME programs, webinars, and case studies are available.
-
Klein, et al., Urol Oncol. 2022 Sep;40(9):408.e9 408.e18.
-
Benidir et al., Urology. 2023 Jun;176:115-120
-
Abdallah, et al., Urology Jan15:S0090 4295(25)00031-7.
|
|
|
This material concerns the IsoPSA Test, a laboratory developed test (LDT) from Cleveland Diagnostics, Inc., which is performed by CLIA-certified laboratories qualified to conduct high-complexity clinical testing and is only intended for use consistent with applicable CLIA requirements. When offered as an LDT, the IsoPSA Test has not been cleared or approved by the U.S. Food and Drug Administration (FDA).
|
|
|
|
